GleamWall
中文EN

VERU VERU INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 863894 · Fiscal year ends 09/30

Financial factors as of 2024-09-30 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY3.6%
TTM net income YoY59.4%
TTM EPS YoY—
Revenue 3-yr CAGR-34.9%
Net income 3-yr CAGR—

Margins

Gross margin34.7%
Operating margin-214.2%
Net margin-223.9%
FCF margin-129.3%
EBITDA margin-213.0%

Returns

ROE-145.4%
ROA-68.5%
ROIC (approx.)-327.4%
Asset turnover0.31x

Leverage & solvency

Liabilities / assets46.5%
Debt / equity0.00x
Current ratio2.97x
Interest coverage-59.54x

Cash quality & payout

Operating cash flow / net income0.57x
Accruals ratio-29.2%
Payout ratio—
Capex / revenue0.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-06-302026Q22026-03-312026Q12025-12-312025Q4*2025-09-302025Q32025-06-302025Q22025-03-312025Q12024-12-312024Q4*2024-09-30
Income statement
Revenue————$0$0—$6.66M
Cost of revenue———————$3.97M
Gross profit———————$2.69M
R&D expense$4.35M$3.15M$1.34M$2.92M$3.02M$3.93M$5.72M$3.29M
SG&A expense$3.36M$4.07M$4.08M$4.54M$5.01M$5.16M$5.23M$6.25M
Operating income-$7.71M-$7.22M-$5.42M$1.17M-$7.55M-$8.12M-$10.25M-$9.34M
Interest expense———————$169,867
Income tax$0$0$0$0$0$0$0$0
Net income-$6.99M-$2.74M-$5.33M$1.45M-$7.33M-$7.90M-$8.95M-$8.53M
EBITDA-$7.69M-$7.19M-$5.40M$1.20M-$7.52M-$8.09M-$10.18M-$9.28M
EPS (basic)-0.30-0.12-0.26—-0.50-0.54-0.61—
EPS (diluted)————————
Balance sheet
Cash & equivalents$23.88M$27.60M$32.99M$15.79M$15.01M$20.02M$26.61M$24.92M
Receivables———————$3.96M
Inventory———————$4.14M
Current assets$27.23M$33.36M$36.81M$18.92M$16.19M$21.38M$28.38M$35.22M
PP&E, net$280,227$308,421$336,615$364,808$393,381$422,712$452,043$481,372
Goodwill$6.88M$6.88M$6.88M$6.88M$6.88M$6.88M$6.88M$6.88M
Intangibles———————$0
Total assets$37.03M$43.08M$47.57M$29.84M$27.33M$32.67M$39.83M$60.42M
Current liabilities$6.16M$5.39M$7.13M$7.79M$6.68M$5.62M$6.35M$11.87M
Total liabilities$8.65M$8.30M$10.44M$11.50M$11.99M$11.62M$13.20M$28.10M
Shareholders' equity$28.38M$34.79M$37.12M$18.33M$15.34M$21.05M$26.63M$32.32M
Shares outstanding17.05M16.05M16.05M14.65M14.65M146.58M146.38M14.64M
Cash flow statement
Operating cash flow-$5.47M-$8.91M-$6.17M-$5.49M-$5.48M-$7.74M-$11.33M-$4.37M
Capital expenditure$0$0$0$0$0$0$1,083$63,036
Free cash flow-$5.47M-$8.91M-$6.17M-$5.49M-$5.48M-$7.74M-$11.33M-$4.43M
Investing cash flow$1.80M$3.52M$0$6.28M$474,064$1.15M$17.25M$131,500
Financing cash flow-$51,914$0$23.37M$0$0$0-$4.22M$0
Depreciation & amortization$28,000$28,000$28,193$28,573$29,000$29,000$64,870$65,144
Stock-based compensation$577,969$402,712$757,605$1.53M$1.67M$2.22M$2.67M$3.23M

Free plan shows the latest 8 periods; Pro shows all 67 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.